• Free shipping from $200
  • collecting affordable offers from best manufacturers worldwide
  • Special offers every week
Your cart

Category: News and Releases

EyeGate Pharma Reports Second Quarter 2019 Financial Results and Provides Business Update

WALTHAM, MA, August 8, 2019 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended June 30, 2019 and provided an update on recent corporate and operational activities. Stephen From, Chief Executive Officer of…

EyeGate Pharma Reports Second Quarter 2020 Financial Results and Provides Business Update

WALTHAM, MA, August 6, 2020 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended June 30, 2020 and provided an update on recent corporate and operational activities. Stephen From, Chief Executive Officer of…

EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

WALTHAM, MA, August 12, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended June 30, 2021 and provided an update on…

EyeGate Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update

WALTHAM, MA, November 7, 2019 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended September 30, 2019 and provided an update on recent corporate and operational activities. Stephen From, Chief Executive Officer of…

EyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business Update

WALTHAM, MA, November 9, 2020 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended September 30, 2020 and provided an update on recent corporate and operational activities. Third Quarter 2020 and Recent Business…

EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel

WALTHAM, Mass., March 08, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that it has submitted an amended Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for a…

EyeGate Pharma Reports First Quarter 2020 Financial Results and Provides Business Update

WALTHAM, MA, May 6, 2020 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended March 31, 2020 and provided an update on recent corporate and operational activities. Stephen From, Chief Executive Officer of…

EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation

  Patent to Provide Broad Coverage for Steroid Delivered Via Ocular Iontophoresis WALTHAM, Mass., July 24, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc.(OTCQB:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has received a…

EyeGate Pharma Regains Nasdaq Listing Compliance

WALTHAM, Mass., Sept. 23, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that the Company has regained compliance with Nasdaq Listing Rule 5550 (a)(2), which concerns minimum bid price listing requirements. “We are pleased to be…

EyeGate Pharma Reports First Quarter 2019 Financial Results and Provides Business Update

WALTHAM, MA, May 8, 2019 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the quarter ended March 31, 2019 and provided an update on recent corporate and operational activities. Stephen From, EyeGate’s Chief Executive Officer, said, “During the first quarter of 2019, we continued to execute on our…